[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fBymKUG0ytJqGxSc5-p4ZHcxnXhDGgcYXs-Rq0Yyjx5Q":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"The Leeds Teaching Hospitals NHS Trust",[4],99,false,9,1,25763,0,92,[14,17,19,22,24,26,29,31],{"name":15,"count":16},"Breast Cancer",4,{"name":18,"count":16},"Cystic Fibrosis",{"name":20,"count":21},"Cancer",3,{"name":23,"count":21},"Surgery",{"name":25,"count":21},"Multiple Sclerosis",{"name":27,"count":28},"Pain",2,{"name":30,"count":28},"Cardiovascular Diseases",{"name":32,"count":28},"Dementia",[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,69,87,113,138,162,187,211,236,254],{"intervention":43,"totalTrials":9,"cells":44},"Methotrexate",{"EARLY_PHASE1":45,"PHASE1":47,"PHASE2":49,"PHASE3":51,"PHASE4":65,"NA":67},{"trials":46,"activeCount":11},[],{"trials":48,"activeCount":11},[],{"trials":50,"activeCount":11},[],{"trials":52,"activeCount":11},[53],{"nctId":54,"briefTitle":55,"status":56,"phases":57,"primaryCompletion":58,"completion":58,"start":59,"enrollment":60,"conditions":61,"interventions":63},"NCT04108468","GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA","COMPLETED",[38],"2023-07","2015-10-27",84,[62],"Psoriatic Arthritis",[43,64],"Golimumab",{"trials":66,"activeCount":11},[],{"trials":68,"activeCount":11},[],{"intervention":64,"totalTrials":9,"cells":70},{"EARLY_PHASE1":71,"PHASE1":73,"PHASE2":75,"PHASE3":77,"PHASE4":83,"NA":85},{"trials":72,"activeCount":11},[],{"trials":74,"activeCount":11},[],{"trials":76,"activeCount":11},[],{"trials":78,"activeCount":11},[79],{"nctId":54,"briefTitle":55,"status":56,"phases":80,"primaryCompletion":58,"completion":58,"start":59,"enrollment":60,"conditions":81,"interventions":82},[38],[62],[43,64],{"trials":84,"activeCount":11},[],{"trials":86,"activeCount":11},[],{"intervention":88,"totalTrials":9,"cells":89},"Growth Hormone Therapy",{"EARLY_PHASE1":90,"PHASE1":92,"PHASE2":94,"PHASE3":96,"PHASE4":98,"NA":100},{"trials":91,"activeCount":11},[],{"trials":93,"activeCount":11},[],{"trials":95,"activeCount":11},[],{"trials":97,"activeCount":11},[],{"trials":99,"activeCount":11},[],{"trials":101,"activeCount":11},[102],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":112},"NCT02049671","Elucidation of the Effects of Growth Hormone (GH) Deficiency and GH Replacement on Clot and Platelet","UNKNOWN",[],"2020-07-30","2013-06-01",150,[111],"Hypopituitary Adults",[88],{"intervention":114,"totalTrials":9,"cells":115},"rimantadine",{"EARLY_PHASE1":116,"PHASE1":118,"PHASE2":120,"PHASE3":122,"PHASE4":124,"NA":126},{"trials":117,"activeCount":11},[],{"trials":119,"activeCount":11},[],{"trials":121,"activeCount":11},[],{"trials":123,"activeCount":11},[],{"trials":125,"activeCount":11},[],{"trials":127,"activeCount":11},[128],{"nctId":129,"briefTitle":130,"status":56,"phases":131,"primaryCompletion":132,"completion":132,"start":133,"enrollment":134,"conditions":135,"interventions":137},"NCT01413490","Hepatitis C Rimantadine and Antiviral Combination Therapy",[],"2015-03","2012-05",10,[136],"Hepatitis C",[114],{"intervention":139,"totalTrials":9,"cells":140},"Amoxicillin",{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":149,"NA":151},{"trials":142,"activeCount":11},[],{"trials":144,"activeCount":11},[],{"trials":146,"activeCount":11},[],{"trials":148,"activeCount":11},[],{"trials":150,"activeCount":11},[],{"trials":152,"activeCount":11},[153],{"nctId":154,"briefTitle":155,"status":56,"phases":156,"primaryCompletion":157,"completion":157,"start":158,"enrollment":109,"conditions":159,"interventions":161},"NCT03607734","Penicillin Allergy De-Labelling in Elective Surgical Patients (PADLES)",[40],"2017-10-02","2017-04-24",[160],"Allergy",[139],{"intervention":163,"totalTrials":9,"cells":164},"Staple Group",{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":171,"PHASE4":173,"NA":175},{"trials":166,"activeCount":11},[],{"trials":168,"activeCount":11},[],{"trials":170,"activeCount":11},[],{"trials":172,"activeCount":11},[],{"trials":174,"activeCount":11},[],{"trials":176,"activeCount":11},[177],{"nctId":178,"briefTitle":179,"status":56,"phases":180,"primaryCompletion":181,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":186},"NCT02046239","Suture vs Staples for Skin Closure After Liver Resection",[40],"2015-01-01","2013-03-01",200,[185],"Closure of the Skin After Liver Resection",[163],{"intervention":188,"totalTrials":9,"cells":189},"ivabradine",{"EARLY_PHASE1":190,"PHASE1":192,"PHASE2":194,"PHASE3":196,"PHASE4":198,"NA":200},{"trials":191,"activeCount":11},[],{"trials":193,"activeCount":11},[],{"trials":195,"activeCount":11},[],{"trials":197,"activeCount":11},[],{"trials":199,"activeCount":11},[],{"trials":201,"activeCount":11},[202],{"nctId":203,"briefTitle":204,"status":105,"phases":205,"primaryCompletion":206,"start":207,"conditions":208,"interventions":210},"NCT02086422","Iatrogenic Chronotropic Incompetence and Exercise Tolerance in Heart Failure",[40],"2015-07","2013-07",[209],"Chronic Heart Failure",[188],{"intervention":212,"totalTrials":9,"cells":213},"Amikacin",{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":220,"PHASE4":222,"NA":224},{"trials":215,"activeCount":11},[],{"trials":217,"activeCount":11},[],{"trials":219,"activeCount":11},[],{"trials":221,"activeCount":11},[],{"trials":223,"activeCount":11},[],{"trials":225,"activeCount":11},[226],{"nctId":227,"briefTitle":228,"status":105,"phases":229,"primaryCompletion":230,"start":231,"conditions":232,"interventions":233},"NCT02489955","Antibiotic Nephrotoxicity in Adult Patients With Cystic Fibrosis",[40],"2017-02","2015-02",[18],[212,234,235],"Tobramycin","Colomycin",{"intervention":234,"totalTrials":9,"cells":237},{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":244,"PHASE4":246,"NA":248},{"trials":239,"activeCount":11},[],{"trials":241,"activeCount":11},[],{"trials":243,"activeCount":11},[],{"trials":245,"activeCount":11},[],{"trials":247,"activeCount":11},[],{"trials":249,"activeCount":11},[250],{"nctId":227,"briefTitle":228,"status":105,"phases":251,"primaryCompletion":230,"start":231,"conditions":252,"interventions":253},[40],[18],[212,234,235],{"intervention":235,"totalTrials":9,"cells":255},{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":262,"PHASE4":264,"NA":266},{"trials":257,"activeCount":11},[],{"trials":259,"activeCount":11},[],{"trials":261,"activeCount":11},[],{"trials":263,"activeCount":11},[],{"trials":265,"activeCount":11},[],{"trials":267,"activeCount":11},[268],{"nctId":227,"briefTitle":228,"status":105,"phases":269,"primaryCompletion":230,"start":231,"conditions":270,"interventions":271},[40],[18],[212,234,235]]